hat
Sou 26 jen, 2015, Mitsubishi Tanabe Pharma Corporation te anonse li te resevwa apwobasyon nan mache Radicut pou tretman nan ALS nan Japon. Faz III klinik jij la te kòmanse an 2011 nan Japon. Konpayi an te akòde Deziyasyon Dwòg Òfelen pou Radicut pa FDA a ak Inyon Ewopeyen an nan 2015. Radicut se yon dwòg venn ak administre 14 jou ki te swiv pa 14 jou jou ferye dwòg.
eng
On June 26, 2015, Mitsubishi Tanabe Pharma Corporation announced it has received approval to market Radicut for treatment of ALS in Japan. The phase III clinical trial began in 2011 in Japan. The company was awarded Orphan Drug Designation for Radicut by the FDA and EU in 2015. Radicut is an intravenous drug and administrated 14 days followed by 14 days drug holiday.